摘要
目的:探讨Oligofectamine介导的血管内皮生长因子(VEGF)反义寡核苷酸(ASODN)转染对人胆囊癌GBC-SD细胞裸鼠移植瘤的生长及VEGF、Flt-1和KDR表达的影响。方法:通过裸鼠皮下接种体外培养的人胆囊癌GBC-SD细胞建立人胆囊癌裸鼠移植瘤模型,并将裸鼠分为对照组(A组)、VEGF SODN+Oligifectamine组(B组)和VEGF ASODN+Oligifectamine组(C组),各组裸鼠在接种后24h内,在接种部位皮下分别缓慢注射200μl磷酸缓冲液(PBS)、VEGF SODN100μg+Oligofectamine0.5μl(总体积为200μl)及VEGF ASODN100μg+Oligofectamine0.5μl(总体积为200μl),每3天1次,连续治疗5周,观察各组裸鼠的成瘤性、体积及瘤重的变化,并运用免疫组化技术检测胆囊癌裸鼠移植瘤中VEGF、Flt-1和KDR的表达变化。结果:A、B、C组裸鼠2周时的成瘤率分别为87.5%、87.5%和37.5%,C组显著低于A、B组(P<0.05),5周时各组的成瘤率均为100%。各组裸鼠移植瘤5周时的体积和瘤重分别为:A组(253.49±27.11)mm3和(1.96±0.17)g,B组(255.84±26.51)mm3和(1.86±0.21)g,C组(125.45±17.49)mm3和(0.97±0.13)g,C组显著低于A、B组(P<0.05),C组的抑瘤率为(50.79±9.19)%。A、B组裸鼠移植瘤VEGF、Flt-1和KDR的表达均无统计学差异(P>0.05),而C组裸鼠移植瘤VEGF、Flt-1和KDR的表达较A、B组明显减弱(P<0.05)。结论:VEGF ASODN在体内能显著抑制人胆囊癌裸鼠移植瘤的增殖,降低其在裸鼠体内的成瘤性,抑制VEGF、Flt-1和KDR在蛋白水平的表达,抑制裸鼠移植瘤的生长及血管的形成。
Objective： To investigate the effect of of oligofectamine mediated VEGF SODN transfection on the growth, VEGF, Flt-1 and KDR protein expression of GBC-SD cells transplant tumor of nude mice in vivo. Methods.. GBC-SD cells were injected subcutaneously into nude mice to establish successfully transplant tumor model of gallbladder carcinoma. All mice were divided randomly into A group （control）, B group（VEGF SODN＋Oligifectamine） and C group（VEGF ASODN＋Oligifectamine）. The mice of A, B and C group were injected 200μl PBS, VEGF SODN 100 μg＋Oligofectamine 0.5 μl（volume 200μl and VEGF ASODN 100μg＋Oligofectamine 0. 5 μl（total volume 200 μl into the spot of GBC-SD cells inocμlation in 24 h respectively. The therapy was done one time every 3 days and last 5 weeks continuously. The incidence, weight and volume of transplant tumor of all mice were observed and measured, meantime, the VEGF, Flt-1 and KDR protein expression were tested by immunohistochemistry. Results： The incidences of transplant tumor in mice of group A, B and C were 87.5%, 87.5% and 37.5% respectively in 2 weeks. The difference was significant in mice of group C as compared to that of group A and B （P 〈0.05）. The incidences of transplant tumor in mice of group A, B and C were all 100% in 5 weeks. The volume and weight of transplant tumors of group A, B and C were （253. 49±27. 11） mma and （1.96±0.17） g, （255.84±26.51）rama and （1.86±0.21）g,（125.45±17.49）rama and （0.97±0.13）g respectively, which was significantly different in group C as compared to that of group A and B as well （P 〈0.05）. The VEGF, Flt-1 and KDR protein expression of transplant tumor had not any difference between group A and B （P 〉0.05）, but as for group C, the VEGF, Flt-1 and KDR protein expression were significantly inhibited as compared to those of group A and B （P G0.05）. Conclusion： VEGF ASODN could significantly inhibit proliferation and incidence of transplant gallbladder carcinoma, inhibit the VEGF, Flt-1 and KDR protein expression of transplant tumor.
出处
《新疆医科大学学报》
CAS
2007年第3期220-224,共5页
Journal of Xinjiang Medical University
